Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 9 Prostatic Neoplasms 5 Neoplasms 5 Neoplasm Metastasis 4 Advanced Solid Tumors 4 Leukemia, Myeloid, Acute 3 Triple Negative Breast Neoplasms 2 Pancreatic Neoplasms 2 Ovarian Neoplasms 2 Carcinoma, Renal Cell 2 Solid Tumor 1 Small Cell Lung Carcinoma 1 Sarcoma, Ewing 1 Recurrent Squamous Cell Lung Carcinoma 1 Neuroectodermal Tumors, Primitive, Peripheral 1 Myelodysplastic Syndromes 1 Lymphoma, Mantle-Cell 1 Lung Neoplasms 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Kidney Neoplasms 1 Glioma 1 Glioblastoma 1 Fanconi Anemia, Complementation Group D1 1 Fallopian Tube Neoplasms 1 Colorectal Neoplasms 1 Childhood Solid Tumors 1 Central Nervous System Neoplasms 1 Carcinoma, Ovarian Epithelial 1 Breast Adenocarcinoma 1 Advanced Solid Tumor 1

Interventions

Temozolomide 203 Radiotherapy 118 Bevacizumab 93 Radiation 40 Magnetic Resonance Spectroscopy 28 Irinotecan 27 Carmustine 25 Surgical Procedures, Operative 24 Lomustine 21 Erlotinib Hydrochloride 19 Chemotherapy, Adjuvant 18 Carboplatin 17 temsirolimus 13 Drug Therapy 13 O(6)-benzylguanine 12 Nivolumab 12 sargramostim 11 Sirolimus 11 Radiotherapy, Intensity-Modulated 11 Radiotherapy, Conformal 11 Sorafenib 10 Radiosurgery 10 Imatinib Mesylate 10 Everolimus 10 pembrolizumab 9 motexafin gadolinium 9 Vorinostat 9 Thalidomide 8 IL13-PE38 8 Gefitinib 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Glioblastoma × talazoparib × Clear all

NCT04740190 2025-06-11

TAC-GReD

The University of Hong Kong

Phase 2 Completed

Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡